Recursion Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXRX research report →
Range $5.9 – $5.9
Price Chart
About the company
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
- CEO
- Najat Khan
- IPO
- 2021
- Employees
- 600
- HQ
- Salt Lake City, UT, US
AI snapshot
Six angles, distilled from the data.
RXRX remains in a multi-month downtrend and is still below its 200-day moving average of 3.4563, with the share price closer to the 52-week low of 2.50 than the high of 5.24. The setup is still defensive, though the stock has stabilized after a long slide from higher levels.
Street sentiment is cautious: the consensus is Hold, with 4 Buys and 6 Holds and no Sell ratings. The average target sits at 5.9, above the current share price, but recent target moves have been mixed, including Morgan Stanley lifting its target to 5.90 after prior cuts.
The earnings pattern is uneven but workable, with RXRX beating 5 of the last 8 quarters. Next-year EPS estimates remain negative at -0.8084, so shareholders should watch for continued loss control and any sign that revenue growth can outpace cash burn.
The pattern leans negative on discretion: there were 5 sales and no open-market buys. Recent activity is dominated by automatic award, vesting, and in-kind transactions, while the discretionary sales from directors and the CEO point to some caution at current levels.
Profitability remains deeply challenged, with a gross margin of -516.8% and operating margin of -7.3417. Revenue still grew 2.585% year over year, but operating cash flow was -371.8 million and free cash flow was -365.3 million, so execution on burn reduction matters more than headline growth.
RXRX competes as a platform-driven biotech, but it still trades like a pre-profit story rather than a mature peer. The balance sheet is a relative strength with 743.3 million in cash and net cash of 665.3 million, while valuation remains tied to pipeline progress and sentiment.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.53B
- P/E
- -2.81
- PEG
- -0.04
- P/S
- 23.05
- P/B
- 1.51
- EV/EBITDA
- -2.70
- Div Yield
- 0.00%
- Gross Margin
- 10.74%
- Op Margin
- -725.44%
- Net Margin
- -697.13%
- ROE
- -47.85%
- ROIC
- -43.66%
Latest fiscal year · YoY change
- Revenue
- $74.68M+26.9%
- Gross Profit
- $-46,273,000-440.2%
- Op Income
- $-648,132,000
- Net Income
- $-644,759,000-39.1%
- EPS
- $-1.44+14.8%
- OCF Growth
- -3.5%
- FCF Growth
- -1.5%
- 52W High
- $5.24
- 52W Low
- $2.44
- 50D MA
- $3.73
- 200D MA
- $3.45
- Beta
- 1.03
- RSI (14)
- 32
- Avg Volume
- 24.36M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Recursion reported early clinical proof of concept across two lead programs, with strong FAP polyp reductions, initial oncology responses, and improved partnership and cash visibility.· November 3, 2026
- REC-4881 showed deep and durable polyp-burden reductions in FAP, including activity in upper and lower GI disease and fewer large high-risk polyps.
- REC-1245 produced three partial responses in heavily pretreated solid-tumor patients, with 11 of 12 response-evaluable patients showing disease control at 8 weeks at 45 mg and above.
- Partnership momentum continued: Sanofi optioned a candidate for $10 million upfront/milestone payment, and Genentech optioned the first neuroscience target from Recursion’s maps.
- Management said the oversubscribed $200 million financing extends cash runway into 2029.
- Recursion lowered 2026 cash operating expense guidance to $375 million and expects 2027 cash operating expense to fall to under $360 million.
Recursion did not provide company-wide revenue or EPS in this transcript. On REC-4881, 13 of 15 evaluable patients, or about 87%, had a reduction in total polyp burden after 12 weeks; about one in three had at least a 65% reduction, and roughly 85% still had lower polyp burden about 12 weeks after stopping treatment. Upper GI polyp burden fell in 92% of evaluable patients, with median reductions of about 55% in the upper GI and 50% in the lower GI; 6 of 8 patients with baseline polyps larger than 5 mm had fewer of those polyps at week 13, and 4 saw counts fall by at least 80%. Safety for REC-4881 at 4 mg QD showed 21 of 26 safety-evaluable patients (about 81%) with Grade 1 or 2 treatment-related side effects; 4 patients had Grade 3 events, and there were no Grade 4 or 5 treatment-related AEs. For REC-1245, Recursion reported 3 partial responses, including 2 confirmed PRs in endometrial cancer and 1 unconfirmed PR in hepatocellular carcinoma; disease control at 8 weeks was 91.7% (11 of 12) at doses of 45 mg and above. Safety data for REC-1245 showed the 65 mg dose exceeded MTD, while 45 mg was selected for expansion with no serious treatment-related adverse events and no dose reductions reported. Partnership inflows exceeded $535 million cumulatively, and Sanofi’s option triggered a $10 million payment, bringing total upfront and milestone payments from Sanofi to $144 million. Management also said cash runway now extends into 2029 after the oversubscribed $200 million financing in October. The company lowered 2026 cash operating expense guidance from $390 million to $375 million and now expects 2027 cash operating expense to be under $360 million.
Najat Khan framed the quarter as evidence that Recursion’s AI platform is becoming repeatable across biology, chemistry, and the clinic, not just in isolated programs. She emphasized that the company now has positive clinical data from two first-in-class programs, plus external validation through Sanofi and Genentech collaborations. Her tone was confident and strategic, centered on building a “single engine” that can generate biology insights, design molecules, and produce clinically meaningful data repeatedly.
No standalone CFO remarks were included in the transcript, but management provided key financial and capital-allocation updates. Recursion said it completed an oversubscribed $200 million financing in October, expects cash runway to extend into 2029, and reduced 2026 cash operating expense guidance from $390 million to $375 million. Looking ahead to 2027, it expects cash operating expense to come down further to under $360 million. Management also noted more than $535 million in cumulative partner cash inflows and more than $100 million earned across nine milestones in roughly two years.
In the KOL discussion, analysts and clinicians focused on whether the observed polyp reductions in FAP are meaningful clinically, how durable the effect is after stopping drug, and how much safety patients would tolerate. Dr. Katona said any reduction in polyps is meaningful in practice because treatment decisions in FAP are driven by polyp burden, including surveillance intervals and surgery timing, and he viewed the durability signal as encouraging for a chemopreventive agent. On safety, he said tolerance depends on disease severity: patients facing major surgery or very frequent endoscopy may accept more side effects than those with milder disease. Both KOLs stressed there is still a large unmet need for medical therapy in FAP, especially post-colectomy patients with upper GI disease.
The strongest bull case from this call is that Recursion now has two programs with visible human data: REC-4881 in FAP and REC-1245 in oncology. Management and external experts both highlighted meaningful clinical signals, and the FAP results showed durability after treatment stopped, which could matter for chronic management. The company also pointed to major partnership validation, a large cash runway, and lower future cash burn.
The main risks are that both programs are still early and need more data before any registrational or commercial conclusion. REC-4881 still has tolerability issues, including Grade 3 events and discontinuations earlier in the study, while REC-1245 reached an MTD at 65 mg and had no activity below 45 mg. The company also remains dependent on continued clinical execution, FDA alignment for the FAP registrational study, and successful advancement of partner programs that are still several years from potential launch.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.9%
- Shares Outstanding
- 622.76M
- Float Shares
- 560.07M
of shares held by institutions
364 13F filers
Buy/sell ratio 0.57. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 53.48M | ▲ 3.17M |
| Vanguard Group Inc | 47.19M | ▲ 7.41M |
| Ark Investment Management LLC | 44.75M | ▲ 3.41M |
| Vanguard Portfolio Management LLC | 35.81M | ▲ 4.68M |
| State Street Corp | 30.00M | ▼ 4.70M |
| Vanguard Capital Management LLC | 23.00M | ▲ 238.43K |
| Baillie Gifford & Co | 18.17M | ▼ 5.31M |
| Geode Capital Management, LLC | 13.91M | ▲ 94.71K |
| Softbank Group Corp. | 13.64M | 0 |
| Fmr LLC | 11.44M | ▲ 11.39M |
| Ubs Group AG | 8.43M | ▼ 517.08K |
| Mic Capital Management Uk Llp | 8.26M | ▼ 1.39M |
Held by 389 ETFs
Biggest fund positions in RXRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Taylor Ben R | other | 25,018 |
| Nov 16, 26 | Hallett David | other | 26,657 |
| Nov 16, 26 | Khan Najat | other | 85,815 |
| Nov 2, 26 | Hassan Fred | other | 156,658 |
| Nov 3, 26 | Borgeson Blake | sell | 40,000 |
| Oct 31, 26 | Hassan Fred | other | 0 |
| Oct 6, 26 | Borgeson Blake | sell | 50,000 |
| Oct 6, 26 | HERSHBERG ROBERT | other | 25,000 |
| Oct 6, 26 | HERSHBERG ROBERT | other | 25,000 |
| Oct 6, 26 | HERSHBERG ROBERT | sell | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RXRX coverage
Recent articles, reports, and earnings notes.

Nordicus Partners IPO: What Investors Need to Know
Nordicus Partners Corporation (NASDAQ: NORD) is expected to list on 2026-10-30, but the company has not disclosed a price range yet. The story is less a classic IPO and more a microcap biotech holding-company setup tied to Nordic life sciences assets. Bull case: asset-backed biotech optionality; bear case: no disclosed terms, nominal revenue, and going-concern risk.

Iambic Therapeutics IPO Preview: AI Drug Discovery Meets Clinical Risk
Iambic Therapeutics Inc. (NASDAQ: IAM) is expected to list on 2026-10-15, and the IPO has priced at $16.00 per share after offering 9,375,000 shares. The company did not disclose a price range in the materials provided. The bull case is a fast-growing collaboration platform with clinical-stage assets; the bear case is that it still has to prove AI can translate into durable drug wins.

Nvidia's Secret Partner, Revealed: What Stock Is Keith Kohl Teasing in Topline Trader?
Keith Kohl of Angel Publishing's Topline Trader is promoting “Nvidia's Secret Partner,” also known as the “AI Doctor” pitch. We identify the company and test the claims.
Want a deeper read on RXRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
fool.com · Nov 18
Why Recursion Pharmaceuticals Stock Is Up Today
fool.com · Nov 18
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
globenewswire.com · Nov 18
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Break Below 200-Day Moving Average – Should You Sell?
defenseworld.net · Nov 13
2 healthcare stocks to turn $10 into $100 by next year
finbold.com · Nov 11
Recursion to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 11
Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis
defenseworld.net · Nov 6
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice